Janssen Highlights Latest Research for TREMFYA® (guselkumab) and Investigational Targeted Oral Peptide JNJ-2113 in Moderate to Severe Plaque Psoriasis at the European Academy of Dermatology and Venereology (EADV) Congress ...Middle East

30 presentations showcase breadth of data from Janssen's Immunodermatology pipeline across five commercialized and investigational therapies SPRING HOUSE, Pa., Oct. 9, 2023 /PRNewswire/ -- Janssen Pharmaceuticals, Inc., a Johnson & Johnson company, today announced that 30...

Hence then, the article about janssen highlights latest research for tremfya guselkumab and investigational targeted oral peptide jnj 2113 in moderate to severe plaque psoriasis at the european academy of dermatology and venereology eadv congress was published today ( Monday 09/10/2023 - 02:40 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Janssen Highlights Latest Research for TREMFYA® (guselkumab) and Investigational Targeted Oral Peptide JNJ-2113 in Moderate to Severe Plaque Psoriasis at the European Academy of Dermatology and Venereology (EADV) Congress )

Also on site :

• Bagel Bites Debuts New Snack Style That Has Fans 'Salivating'
• Russia reveals scope of upcoming international security forum
• From Pakistan to Shanghai: A CAR-T Journey Fighting Relapsed Lymphoma